Back to Locations

Indiana University Cancer Center

Indiana Cancer Pavilion - Indianapolis, IN 46202
Website: http://cancer.iu.edu

For information about clinical trials being conducted in Indianapolis, IN, please contact Kerry Bridges at 317.274.2552.


Lawrence Einhorn, MD (Principal Investigator)

Trials at this Location:


Disease: Banking / Biorepository
A Biological Sample Collection Protocol of Patients with and without Metastatic Solid Organ Malignancies - BNK09-138
Status: Open to Accrual 10-06-2009; 124 of 200 accrued.
More Details
Disease: Breast
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic - BRE-126
Status: Open to Accrual at Limited Institutions Only - Open to Accrual 06-26-2009; 21 of 44 accrued.
More Details
Disease: Breast
PARP Inhibition after Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer or ER/PR +, HER2 negative with known BRCA1/2 Mutations - BRE09-146
Status: Opened 2/22/2010; 7 of 135 Accrued
More Details
Disease: Breast
Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study - DoD COE-01
Status: Open to Accrual at Limited Institutions Only - Open to Accrual 09-27-2005 - 76 of 133 Patients Accrued
More Details
Disease: Breast
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative - DoD COE-03 (BRE-126)
Status: Open to Accrual at Limited Institutions Only - Open to Accrual 06-26-2009; 21 of 44 accrued.
More Details
Disease: Colorectal
A Phase I / Randomized Phase II Study of Second Line Therapy with Irinotecan and Cetuximab with or without RAD001 (an mTOR Inhibitor) for Patients with Metastatic Colorectal Cancer - GI05-102
Status: Suspended to Accrual to control accrual to cohort; Originally opened to Accrual 08-02-2007 - 27 of 119 Patients Accrued
More Details
Disease: Bladder
A Pilot Study of Neoadjuvant Dasatinib Followed by Radical Cystectomy for Transitional Cell Carcinoma of the Bladder - GU07-122
Status: Open to Accrual 08-21-2008 at Limited Institutions Only - 15 of 25 Patients Accrued
More Details
Disease: Bladder
Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) - GU07-123
Status: Original Open to IU only as of 12/19/2008; Accrual 7 of 46
More Details
Disease: Bladder
Phase II Trial of Docetaxel plus ASA404 as Second-Line Therapy in Patients with Advanced Urothelial Carcinoma - GU09-144
Status: SUSPENDED to further accrual 04/08/2010; Open to Accrual 03/31/2010
More Details
Disease: Renal
Phase I/II Study of BNC105P in Combination with Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors. - GU09-145
Status: Open to Accrual 1-20-2010; 3 of 138 accrued.
More Details
Disease: Lung
A Randomized Double Blind Phase II Trial of Cisplatin plus Etoposide with/without Concurrent ZD6474 in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer - LUN06-113
Status: Open to Accrual - 01-23-2008 - 35 of 74 Patients Accrued
More Details
Disease: Lung
Phase I Study of Amrubicin and Cyclophosphamide in Patients with Advanced Solid Organ Malignancies - LUN07-130
Status: Suspended to control enrollment to cohort; contact PM; Original open date 02/02/09; 34 of 34 Patients Accrued
More Details
Disease: Lung
A Phase II study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer - LUN08-129
Status: Open to Accrual - 7 of 44 Patients Accrued
More Details
Disease: Lung
A Phase 1b/ 2 Study of AMG 479 in Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer - LUN08-137
Status: Permenately suspended to further accrual effective 7/27/2010; 12 patients accrued
More Details
Disease: Multiple Myeloma
A Phase I/II trial of Bendamustine in Combination with Bortezomib and Pegylated Liposomal Doxorubicin (Doxil) in Patients with Relapsed or Refractory Multiple Myeloma - MM08-141
Status: Open to Accrual 03/05/2010
More Details
Disease: Supportive Care
A Phase III Study Evaluating Aprepitant + a 5HT3 + Dexamethasone for Patients with Germ Cell Tumors Undergoing 5-day Cisplatin Based Chemotherapy Regimens - QL05-37
Status: Open to Accrual - 12-06-2007 - 64 of 71 Patients Accrued
More Details
Disease: Testis
A Phase III Study Evaluating Aprepitant + a 5HT3 + Dexamethasone for Patients with Germ Cell Tumors Undergoing 5-day Cisplatin Based Chemotherapy Regimens - QL05-37
Status: Open to Accrual - 12-06-2007 - 64 of 71 Patients Accrued
More Details